Femasys amends convertible notes, removes anti-dilution, issues 16.4M warrants at $0.58; board adds director

FEMASYS INC

Omnibus Amendment removes Share Combination Event Adjustment from $10.5M+ senior secured convertible notes and warrants, effective Dec 31, 2025.
As consideration, lenders receive 16,378,563 Series D-1 Warrants exercisable at $0.58 per share (Nasdaq minimum price on March 19, 2026).
Director Joshua Silverman resigned March 17, 2026; no disagreement. Board appointed Kenneth D. Eichenbaum, M.D., effective March 18, 2026.
Amendment expands Securities Purchase Agreement participation right exclusion to cover Series D-1 Warrants and underlying shares.

item 1.01 item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FEMASYS INC amended Omnibus Amendment and Consent Agreement with Consenting Holders (effective 2026-03-19).

Action: amendment
Counterparty: Consenting Holders
Effective: 2026-03-19

Exact text from the filing

On March 19, 2026, the Company entered into an Omnibus Amendment and Consent Agreement (the “Amendment Agreement”) with the holders listed on Schedule I thereto (each, a “Consenting Holder” and collectively, the “Consenting Holders”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-010591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.